伊班膦酸钠治疗绝经妇女骨质疏松的Meta分析

BACKGROUND: Alendronate has a marked enhancing effect on bone mineral density. Ibandronate is the newest (the third generation) bisphosphonates. Evidence-based medicine data on the therapeutic effects of both two drugs remain lacking because of different administration routes and time. OBJECTIVE: To compare the therapeutic effects of ibandronate and alendronate on postmenopausal osteoporosis. METHODS: A computer-based online search was conducted in CNKI, PubMed, CECDB, BMA, VIP, CQVIP, CBM, EMbase, ASP, The Cochrane Library, and EMCC databases from August 1999 to August 2015 to screen the relevant randomized controlled trials. Meta-analysis was performed using Stata/SE version 12.0 software by extracting data from the relevant articles.RESULTS AND CONCLUSION: A total of 10 randomized controlled trials involving 725 patients (ibandronate and alendronate for 379 and 346 patients, respectively) were included. The meta-analysis results showed that bone mineral density was significantly increased (P=0.174, I2= 29.4%, WMD=0.03, 95%CI (0.01-0.04)) at 6 months after treatment and incidence rate of fracture was significantly decreased (P=5.810, I2=0%, OR=0.32, 95%CI: (0.10-1.00)) during 1-year treatment with ibandronate compared with alendronate treatment. However, no significant differences were found between two drug treatments in lumbar spine bone mineral density at 1 year after treatment and the incidence rate of fracture during 6-month treatment. Six-month treatment of ibandronate can improve bone mineral density and reduce the incidence rate of fracture of patients with postmenopausal osteoporosis.中国组织工程研究杂志出版内容重点：组织构建；骨细胞；软骨细胞；细胞培养；成纤维细胞；血管内皮细胞；骨质疏松；组织工程

Ibandronate for postmenopausal osteoporosis: a Meta-analysis